Andere talen Oncotelic Therapeutics, Inc.

Aandelen

OTLC

US6283411097

Vertraagde tijd OTC Markets Andere beurzen 20:37:32 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,0394 ^USD	+2,82%		-6,19%	+2,87%

12/04	Oncotelic Therapeutics, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
25/03	Oncotelic Therapeutics, Inc. Kondigt het verband aan tussen kanker en lupus in glioma-patiënten	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.	29/04
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/04
Oncotelic Therapeutics, Inc. - Linkage of Cancer and Lupus in Gliomas Patients	26/03
Linkage of Cancer and Lupus in Gliomas Patients	25/03
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients	25/03
Invitation to Participate in STOP-PC Clinical Trial	04/03
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	21/02
Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients	16/01
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2023 (Updated)	22/12
Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant	18/12
Oncotelic Therapeutics Announces CEO to Discuss Proprietary AI Technology at Ibero-American Chatbot Summit	29/11
Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.	28/11
Earnings Flash (OTLC) ONCOTELIC THERAPEUTICS Posts Q3 Revenue $70,000	15/11
Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results	15/11
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Oncotelic Therapeutics, Inc. announces tranche update	24-10-23
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023	28-08-23
Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023	25-08-23
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer	23-08-23
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Oncotelic Therapeutics, Inc.

Aandelen

OTLC

US6283411097

Andere talen

Filters